IPWatchdog.com is in the process of transitioning to a newer version of our website. Please be patient with us while we work out all the kinks.

Posts Tagged: "Ampyra"

An entirely screwed up way of viewing the world of innovation

When a product or process worth stealing is created the party that is considered the innovator is the thief and the party that is considered to be standing in the way of innovation is the party that actually invented the thing int he first place. What an entirely screwed up way of viewing the world of innovation!… Obviously, this article was intended to just mention as many patent related buzz words to capture search engine traffic. How else could you pivot from from a discussion of Kyle Bass to a discussion of TC Heartland v. Kraft? … Of course, that doesn’t stop Forbes from saying that patent trolls will be in trouble if the Supreme Court decides “defendants can pull cases from the plaintiff-friendly Eastern Texas district.” But TC Heartland has absolutely nothing to do with the Eastern District of Texas, or Texas, or the South for that matter. And it has absolutely nothing to do with patent trolls either! Of course, you’d never know that from reading Forbes. In fact, you’d think the exact opposite.

PTAB ends Kyle Bass IPRs targeting Acorda patents on Ampyra MS treatment with no findings of obviousness

A panel of administrative patent judges (APJs) at the Patent Trial and Appeal Board (PTAB) issued a final written decision ending a series of inter partes review (IPR) proceedings targeting patents covering a popular multiple sclerosis (MS) treatment developed and sold by Ardsley, NY-based Acorda Therapeutics (NASDAQ:ACOR). The decision strengthens the patent portfolio covering Acorda’s Ampyra pharmaceutical even as competition from generic manufacturers has ramped up in recent months. The IPRs, instituted after petitions from the Kyle Bass-backed Coalition for Affordable Drugs (ADORCA), targeted four patents listed in the U.S. Food and Drug Administration’s (FDA) Orange Book.